Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  HeartWare International Inc    HTWR   US4223681002

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

HeartWare : Schedules First Quarter 2015 Conference Call And Webcast

04/22/2015 | 01:01pm US/Eastern

FRAMINGHAM, Mass., April 22, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2015, at 8:00 a.m. U.S. ET on Thursday, April 30, 2015. The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the first quarter and business outlook. The call may be accessed by dialing 1-877-407-0789 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial +1-201-689-8562.

A live webcast of the call will also be available in the Investor section at the Company's website ( A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's website,

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare(®) Ventricular Assist System features the HVAD(®) pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 41 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at

Christopher Taylor
HeartWare International, Inc.
Phone: +1 508 739 0864

To view the original version on PR Newswire, visit:

SOURCE HeartWare International, Inc.

React to this article
04/22 HEARTWARE : Schedules First Quarter 2015 Conference Call And Webcast
04/22 HEARTWARE : Assigned Patent
04/21 HEARTWARE : How it All Plays Out: Complementary Research on ForceField Energy, T..
04/20 HEARTWARE : Contemporary Results From Commercial HVAD® System Registries Highlig..
04/16 HEARTWARE : HTWR) is Trading Lower on Unusual Volume for April 16
04/16 HEARTWARE : Other Events, Financial Statements and Exhibits (form 8-K)
04/16 HEARTWARE : Achieves Primary Endpoint In The ENDURANCE Destination Therapy Clini..
04/15 HEARTWARE : Assigned Patent
04/10 HEARTWARE : Announces Webcasts At The 35th International Society for Heart and L..
04/09 HEARTWARE : Receives Health Canada Approval For Commercialization Of The HeartWa..
Duration : Period :
HeartWare International In Technical Analysis Chart | HTWR | US4223681002 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes